Baike Biotech announced that the net profit for the first quarter is expected to be 55 million yuan to 65 million yuan, an increase of 199.22% to 253.63% over the previous year. During the reporting period, live attenuated herpes zoster vaccine products were added compared to the same period last year, which enriched the company's vaccine range and boosted the company's overall revenue growth. At the same time, the gross margin of the live attenuated herpes zoster vaccine was high, which helped the company's performance increase year on year.
百克生物：预计第一季度净利润同比增加199.22%到253.63%
Baike Biotech: Net profit for the first quarter is expected to increase 199.22% year-on-year to 253.63%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.